Glenmark receives ANDA approval for generic version of Vesicare® Tablets
21 May 2019 | News
It is a generic version of Vesicare® Tablets, 5 mg and 10 mg, of Astellas Pharma US
Glenmark Pharmaceuticals has been granted final approval by the USFDA for Solifenacin Succinate Tablets, 5 mg and 10 mg, a generic version of Vesicare® Tablets, 5 mg and 10 mg, of Astellas Pharma US, Inc.
According to IQVIATM sales data for the 12 month period ending March 2019, the Vesicare® Tablets, 5 mg and 10 mg market achieved annual sales of approximately $942.7 million.
Glenmark’s current portfolio consists of 154 products authorized for distribution in the U.S. marketplace and 58 ANDA’s pending approval with the U.S. FDA.
